Abstract
Having found that recombinant IGF-I acts in children after acute (Lancet “II: 1170, 1988), short term (Clin Endocr 36: 301, 1992) and long administration (Lancet 339: 1258, 1992), treatment on a long-term basis. Forthwith the results o treatment of 8 prepubertal children (5 M, 3 F) with IGF-I (FK-780 Lot 115707K, Fujisawa Pharm. Co. Osaka, Japan, 120-150 ug/d s.c). The mean (±SD) results for the whole group were:
It is evident that the growth velocity almost doubled (80.2%), the mean height SDS improved by 0.6±0.5 in the presence of a normal bone age advencement. Body fat as measured by subscapular skin (S.S.) decreased by a mean of 2270 while mean body weight increased by 19.6%. The drug was well tolerated and keeping reg hypoglycemia were registered. The growth afected the extremities, the trunk and the headcircumference. The rise of serum procollagen I and III, Alk P-tase are similar to those found during hCM GH deficiency. Thus 1CF-1 mimics the effects of GH, providing that it is its true effector hormone.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Laron, Z., Klinger, B. ONE YEAR TREATMENT WITH ICF-1 OF CHILDREN WITH LARON SYNDROME (LS). Pediatr Res 33 (Suppl 5), S5 (1993). https://doi.org/10.1203/00006450-199305001-00019
Issue Date:
DOI: https://doi.org/10.1203/00006450-199305001-00019